Výsledky vyhledávání - "Rodrigo Andres Ascui"

Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice

Autor: Felipe Reyes, Bettina Müller, Wanda Fernandez, Rodrigo Andres Ascui, Alejandro H. Corvalan, Juan Pablo Miranda, Martín Buchholtz, Jorge M Arancibia, Patrick Werner, Carlos Benavides, Jeannie Slater, Mauricio Cerda, Carlos García, Mary Ann Stevens, Jose Antonio Sola

Publikováno v: ecancermedicalscience

Gastric cancer (GC) is a leading cause of cancer death in Chile. Although recommended in international guidelines since 2006, perioperative chemotherapy was not available to patients in the public health system in Chile until 2016. We conducted an ob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a18cb93a516bae6972bdd9bb54af5c9
http://europepmc.org/articles/PMC8241457

Zobrazit plný text záznamu

Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO)

Autor: P. Betancour, Rodrigo Andres Ascui, I. Araya, Jose Antonio Sola, E. Strube, Mauricio Cerda, J. Miranda, B. Mueller, J. Arancibia

Publikováno v: Annals of Oncology. 30:iv61

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::700f961727922f3db31fcd1d425684fe
https://doi.org/10.1093/annonc/mdz155.222

Zobrazit plný text záznamu

Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer

Autor: Rodrigo Andres Ascui, Carlos del Valle Rojas, Humberto Cerda, Mauricio Emmanuel Burotto Pichun, Patricia Banchero, Ricardo Silva, Mauricio Reyes, Jorge M Arancibia, Osvaldo Rudy Aren

Publikováno v: Journal of Clinical Oncology. 33:8075-8075

8075 Background: The recommended dose for erlotinib of 150 mg was developed based on the maximum tolerated dose (MTD); meanwhile the suggested dose for gefitinib is only one third of its MTD. Studi...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d22456879b2d57a7122a135669c9b7e
https://doi.org/10.1200/jco.2015.33.15_suppl.8075

Zobrazit plný text záznamu

Could methylated reprimo cell-free DNA serve as a novel tumor marker to assess response in locally advanced gastric cancer treated with preoperative chemotherapy?

Autor: Maria J. Maturana, Jorge M Arancibia, Alejandra Alarcon, Jose Antonio Sola, Bettina Müller, Francisca Alfaro, Wanda Fernandez, Rodrigo Andres Ascui, Alejandro H. Corvalan

Publikováno v: Journal of Clinical Oncology. 33:101-101

101 Background: Gastric cancer (GC) is one of the leading causes of cancer death. Perioperative chemotherapy (CT) for locally advanced GC improves curative resection rates and survival compared to surgery alone. Response assessment is challenging and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a4e7effd6f97128b5d3f38b0a7725dc
https://doi.org/10.1200/jco.2015.33.3_suppl.101

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání